Randomized Study of Fluoxetine in Children and Adolescents With Autism
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism.
II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population.
III. Compare the baseline compulsive severity and treatment outcome in these patients.
| Condition | Intervention |
|---|---|
|
Autism |
Drug: fluoxetine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Estimated Enrollment: | 45 |
| Study Start Date: | September 1998 |
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study. All patients receive oral placebo daily during week 0.
Patients are randomized to receive either oral fluoxetine or oral placebo daily on weeks 1-8. Patients then crossover to receive treatment on the other arm during weeks 12-20.
Eligibility| Ages Eligible for Study: | 5 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Meets diagnostic criteria for autism
--Prior/Concurrent Therapy--
Other:
- At least 3 months since prior electroconvulsive therapy
- At least 1 month since prior investigational drugs or treatment with any drug known to cause major organ toxicity
- At least 2 weeks since prior monoamine oxidase inhibitors
- At least 6 weeks since prior long acting phenothiazines
- At least 1 week since prior other psychotropic drugs
- No prior fluoxetine of 20 mg/day for 6 weeks
- At least 6 weeks since prior fluoxetine
- No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)
- No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise permitted)
- Prior participation in another serotonin reuptake inhibitor trial allowed
--Patient Characteristics--
Hematopoietic: No significant hematopoietic disease
Hepatic: No prior or concurrent liver disease
Renal: No prior or concurrent kidney disease
Cardiovascular:
- No significant cardiovascular disease
- No abnormal EKG
Neurological:
- No prior seizure disorder or high risk development of seizures
- No prior cerebrovascular disease
- No prior brain trauma
Other:
- Not pregnant or nursing
- Negative pregnancy test
- No unstable major medical illness or systemic disease
- No moderate or severe mental retardation and motor deficits (IQ less than 50)
- No family history of bipolar disorder
- No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective, organic, or bipolar disorders)
- No significant autoaggressive behavior or serious suicidal risk
- No prior or concurrent gastrointestinal conditions
- No unstable endocrine disease (e.g., hypo or hyperthyroidism)
- No prior or concurrent malignancy
- Must be able to tolerate tapering of psychoactive medication
- No history of hypersensitivity or severe side effects to fluoxetine or other serotonin reuptake inhibitors
- No history of severe personality disorder or noncompliance
Contacts and Locations| United States, New York | |
| Albert Einstein College of Medicine | |
| Bronx, New York, United States, 10461 | |
| Mount Sinai School of Medicine | |
| New York, New York, United States, 10029 | |
| New York University Medical Center | |
| New York, New York, United States, 10016 | |
| Study Chair: | Eric Hollander | Mount Sinai School of Medicine |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00004486 History of Changes |
| Other Study ID Numbers: | 199/14266, MTS-FDR001520, MTS-GCO-96-713 |
| Study First Received: | October 18, 1999 |
| Last Updated: | December 7, 2005 |
| Health Authority: | United States: Federal Government |
Keywords provided by FDA Office of Orphan Products Development:
|
autism neurologic and psychiatric disorders rare disease |
Additional relevant MeSH terms:
|
Autistic Disorder Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders Fluoxetine Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013